---
schema_version: "secwatch.filing_event.v1"
accession: "0001501697-25-000006"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:54:46.944398+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# X4 Pharmaceuticals closes upsized $85M private placement for mavorixafor development and WHIM commercialization

## Summary
- Closed private placement of 11,040,776 shares and 48,852,772 pre-funded warrants for gross proceeds of $85M.
- Purchase price per pre-funded warrant is $1.419; exercise price is $0.001 per share; warrants have no expiration.
- Offering upsized from $60M due to pre-existing investment right from one investor; led by Coastlands Capital with support from existing investors.
- Net proceeds to be used for continued development of mavorixafor for chronic neutropenia and commercialization of WHIM.
- Shares and underlying shares to be registered for resale via an SEC registration statement.

## SEC filing metadata
- accession: 0001501697-25-000006
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000150169725000006/0001501697-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000150169725000006/xfor-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001501697-25-000006
- JSON: https://secwatch.observer/filing/0001501697-25-000006.json
- Plain text: https://secwatch.observer/filing/0001501697-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.